<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733445</url>
  </required_header>
  <id_info>
    <org_study_id>CA180-633</org_study_id>
    <nct_id>NCT02733445</nct_id>
  </id_info>
  <brief_title>Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib</brief_title>
  <official_title>Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine how often and how likely patients are to develop
      Type 2 Diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy
      for Chronic Myelogenous Leukemia (CML).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence rate of new-onset Type 2 Diabetes (T2DM) among patients with Chronic myelogenous leukemia (CML) receiving imatinib as first-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of new-onset Type 2 Diabetes (T2DM) among patients with Chronic myelogenous leukemia (CML) receiving dasatinib as first-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of new-onset Type 2 Diabetes (T2DM) among patients with Chronic myelogenous leukemia (CML) receiving nilotinib as first-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of new-onset Hyperlipidemia (HLD) among patients with Chronic myelogenous leukemia (CML) receiving imatinib as first-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of new-onset Hyperlipidemia (HLD) among patients with Chronic myelogenous leukemia (CML) receiving dasatinib as first-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence rate of new-onset Hyperlipidemia (HLD) among patients with Chronic myelogenous leukemia (CML) receiving nilotinib as first-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence rate of new-onset Type 2 Diabetes (T2DM) among patients with Chronic myelogenous leukemia (CML) receiving dasatinib as first- or second-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of new-onset Type 2 Diabetes (T2DM) among patients with Chronic myelogenous leukemia (CML) receiving nilotinib as first- or second-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of new-onset Hyperlipidemia (HLD) among patients with Chronic myelogenous leukemia (CML) receiving dasatinib as first- or second-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence rate of new-onset Hyperlipidemia (HLD) among patients with Chronic myelogenous leukemia (CML) receiving nilotinib as first- or second-line therapy in a commercially or Medicare insured population</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk comparison of developing Type 2 Diabetes (T2DM) among patients treated with imatinib with respect to patients treated with dasatinib as first-line therapy and as first- or second-line therapy</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk comparison of developing Type 2 Diabetes (T2DM) among patients treated with nilotinib with respect to patients treated with dasatinib as first-line therapy and as first- or second-line therapy</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk comparison of developing Hyperlipidemia (HLD) among patients treated with imatinib with respect to patients treated with dasatinib as first-line therapy and as first- or second-line therapy</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk comparison of developing Hyperlipidemia (HLD) among patients treated with nilotinib with respect to patients treated with dasatinib as first-line therapy and as first- or second-line therapy</measure>
    <time_frame>approximately 101 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2650</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>dasatinib cohort</arm_group_label>
    <description>Patients with CML receiving dasatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nilotinib cohort</arm_group_label>
    <description>Patients with CML receiving nilotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <arm_group_label>dasatinib cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <arm_group_label>nilotinib cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study is based on health insurance claims data, which covers inpatient and outpatient
        claims from a geographically diverse area across the U.S.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  At least 1 prescription for nilotinib or dasatinib between 7/1/2006-12/31/2014

          -  Continuously enrolled in the same health plan throughout the study period

          -  At least 2 diagnosis codes for CML at least 30 days apart as documented in medical
             insurance claims

        Exclusion Criteria:

          -  patients who had a documented diagnosis of diabetes in their medical claims or
             received a medication for diabetes before receiving dasatinib or nilotinib

          -  patients who had a documented diagnosis of high cholesterol/lipids in their medical
             claims or received a medication for high cholesterol/lipids before receiving dasatinib
             or nilotinib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

